234 Church Street
About Biohaven Pharma
79 articles with Biohaven Pharma
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Phase 2 Efficacy Trial Start Planned for Second Quarter 2019
Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
Biohaven Pharmaceutical Holding Company Ltd. announced the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO) inhibitor, which Biohaven is developing as a potential treatment for multiple system atrophy (MSA).
Rimegepant is the first small molecule, orally administered, calcitonin gene-related peptide (CGRP) receptor antagonist potentially being developed for both the acute and preventive treatment of migraine in China
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Biohaven Pharmaceutical Holding Company Ltd. announced today the closing of its underwritten public offering of 3,859,060 of its common shares, including the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $37.25 per share.
Biohaven Pharmaceutical Holding Company Ltd. today announced the pricing of its underwritten public offering of 3,355,705 of its common shares at a price to the public of $37.25 per share.
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.
Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Single dose, proprietary, rimegepant Zydis ODT formulation provided rapid onset of pain relief with numerical separation from placebo as early as 15 minutes and statistically significant by 60 minutes
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
If approved, BHV-0223 would become the only formulation of riluzole that does not require swallowing tablets or liquids, offering an important delivery alternative for the standard-of-care treatment of ALS
Three panels with 13 KOLs highlighting migraine, glutamate and inflammation platforms
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine
Strong and consistent progress continues across multiple drug development platforms with lead calcitonin gene-related peptide (CGRP) receptor antagonist program remaining on timelines for submission of rimegepant new drug application (NDA) in mid-2019
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
BHV-3500 is the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be administered in an intranasal (IN) formulation in human testing
Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut
Novel anti-metallothionein antibody, UC1MT, has the potential to become a first-in-class treatment for a range of inflammatory and autoimmune disorders
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Robert (Bob) Repella to its Board of Directors.
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
BHV-3500 is the first intranasal formulation of a small molecule calcitonin gene-related peptide receptor antagonist to be advanced for human dosing in clinical trials.
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Both pivotal Phase 3 trials show single-dose rimegepant provides rapid and lasting relief from pain and associated symptoms of migraine
Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
Biohaven Pharmaceutical Holding Company Ltd. announced today that it entered into an exclusive, worldwide license agreement, through its subsidiary Biohaven Therapeutics Ltd., with AstraZeneca AB for the development and commercialization rights to AZD3241
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.